publications

Filter by:
Current and anticipated future use of MRD in hematological and solid tumors​

This report explores the current and future use of minimal residual disease (MRD) testing, uncovering adoption trends, clinical applications, and commercial implications.

 
Data & AI Regulatory Insights
Addressing the Economic and
Operational Issues of the
Clinical Practice Gaps in NSCLC

This paper presents five key recommendations to tackle economic and operational barriers hindering access to precision medicine for NSCLC patients.

Commercial Strategy Optimization
The Clinical Practice Gaps in Precision Medicine

Discover What’s Changed Since the Original 64.4% Insight. The Updated Clinical Practice Gaps Report Is Here.

Practice Gaps Publications
The Impact of Clinical Practice Gaps

Our first Practice Gaps study, revealing that 64.4% of patients don't receive the best treatment for them.

Practice Gaps Publications
IVDR Impact Analysis Report

Explore the IVDR's impact on diagnostic practices and patient care in the EU, highlighting potential challenges and the need for awareness among stakeholders following the COVID-19 pandemic.

Regulatory Insights
Precision Oncology Paradigm Report

Explore how a companion diagnostic approach to precision oncology can reduce R&D costs and improve patient outcomes by efficiently targeting treatments to eligible patients.

CE-IVDR Report

Stay updated on the IVDR implementation and its impact on molecular testing, as experts share insights on challenges and future perspectives in the diagnostic landscape.

Regulatory Insights
D-Cubed Full report 2025

Explore D-Cubed Pharma's comprehensive report on how Diagnostics, Data, and Digital transform pharma launch performance and patient access in 2026 and beyond.

By Peter Keeling
Regulatory Insights
Advancing Precision Medicine Adoption in the Asia-Pacific (APAC) Region

Explore strategies and recommendations to enhance precision medicine adoption in the APAC region, improving patient access to testing and treatment solutions.

Commercial Strategy Optimization
Precision Medicine Readiness Report 1

Read the first Precision Medicine Readiness Report, addressing diagnostic ecosystem challenges that hinder patient access and highlighting pharma's ongoing commercial readiness efforts.

Commercial Strategy Optimization
Precision Medicine Readiness Report 2

In the second paper, discover how the Axis for Change manifesto aims to accelerate precision medicine testing from years to months, using NSCLC to highlight diagnostic flaws.

Commercial Strategy Optimization
Precision Medicine Readiness Report 3

Explore the final report of the Axis for Change Manifesto, highlighting advancements in precision medicine and advocating for increased investment in diagnostic pathways for better patient access to treatments.

Commercial Strategy Optimization

Stay ahead with the diaceutics newsletter

Diagnostic-driven therapies are reshaping commercialization. Get evidence-based content, expert perspectives, and practical intelligence delivered straight to your inbox, every two weeks.

Ready to do commercialization differently?

Every patient journey contains opportunities to improve testing, engagement, and adoption. We can help you find themso more people get the right therapy sooner.